These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34790354)

  • 41. Immunohistochemical detection of the BRAF V600E mutation in melanoma patients with monoclonal antibody VE1.
    Liu H; Li Z; Wang Y; Feng Q; Si L; Cui C; Guo J; Xue W
    Pathol Int; 2014 Dec; 64(12):601-6. PubMed ID: 25359093
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of targeted next generation sequencing (NGS) versus isolated BRAF V600E analysis in patients with metastatic melanoma.
    Zhu ML; Zhou L; Sadri N
    Virchows Arch; 2018 Sep; 473(3):371-377. PubMed ID: 29926184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intra- and inter-tumor heterogeneity of BRAF(V600E))mutations in primary and metastatic melanoma.
    Yancovitz M; Litterman A; Yoon J; Ng E; Shapiro RL; Berman RS; Pavlick AC; Darvishian F; Christos P; Mazumdar M; Osman I; Polsky D
    PLoS One; 2012; 7(1):e29336. PubMed ID: 22235286
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preliminary Study on the Identification of BRAF
    Duan J; Yang Y; Yin L; Zhang X; Tang Y; Zhang S; Gong H; Xiao M; Li M; Li Q; Li X; Yang L; Fan Q; Wang Y
    Onco Targets Ther; 2020; 13():13077-13085. PubMed ID: 33376356
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A UK feasibility and validation study of the VE1 monoclonal antibody immunohistochemistry stain for BRAF-V600E mutations in metastatic melanoma.
    Lo MC; Paterson A; Maraka J; Clark R; Goodwill J; Nobes J; Garioch J; Moncrieff M; Rytina E; Igali L
    Br J Cancer; 2016 Jul; 115(2):223-7. PubMed ID: 27336602
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of next-generation sequencing mutation profiling with BRAF and IDH1 mutation-specific immunohistochemistry.
    Jabbar KJ; Luthra R; Patel KP; Singh RR; Goswami R; Aldape KD; Medeiros LJ; Routbort MJ
    Am J Surg Pathol; 2015 Apr; 39(4):454-61. PubMed ID: 25634750
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunohistochemical detection of the BRAF V600E mutant protein in colorectal neoplasms.
    Vakiani E; Yaeger R; Brooke S; Zhou Y; Klimstra DS; Shia J
    Appl Immunohistochem Mol Morphol; 2015 Jul; 23(6):438-43. PubMed ID: 25517872
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BRAF mutations in metastatic malignant melanoma: comparison of molecular analysis and immunohistochemical expression.
    Ehsani L; Cohen C; Fisher KE; Siddiqui MT
    Appl Immunohistochem Mol Morphol; 2014 Oct; 22(9):648-51. PubMed ID: 25046227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pattern-based interpretation of p53 immunohistochemical expression as a surrogate marker for TP53 mutations in colorectal cancer.
    Osakabe M; Yamada N; Sugimoto R; Uesugi N; Nakao E; Honda M; Yanagawa N; Sugai T
    Virchows Arch; 2024 Mar; ():. PubMed ID: 38512505
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular platforms utilized to detect BRAF V600E mutation in melanoma.
    Curry JL; Torres-Cabala CA; Tetzlaff MT; Bowman C; Prieto VG
    Semin Cutan Med Surg; 2012 Dec; 31(4):267-73. PubMed ID: 23174497
    [TBL] [Abstract][Full Text] [Related]  

  • 51. BRAFV600E mutation analysis by immunohistochemistry in patients with thoracic metastases from colorectal cancer.
    Ilie MI; Long-Mira E; Hofman V; Mouroux J; Vignaud JM; Gauchotte G; Begueret H; Merlio JP; Emile JF; Hébuterne X; Hofman P
    Pathology; 2014 Jun; 46(4):311-5. PubMed ID: 24798160
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection of BRAF V600E Mutation in Ganglioglioma and Pilocytic Astrocytoma by Immunohistochemistry and Real-Time PCR-Based Idylla Test.
    Durślewicz J; Klimaszewska-Wiśniewska A; Antosik P; Kasperska A; Grzanka D; Szylberg T; Szylberg Ł
    Dis Markers; 2020; 2020():8880548. PubMed ID: 32879641
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tumor cellularity as a quality assurance measure for accurate clinical detection of BRAF mutations in melanoma.
    Dudley JC; Gurda GT; Tseng LH; Anderson DA; Chen G; Taube JM; Gocke CD; Eshleman JR; Lin MT
    Mol Diagn Ther; 2014 Aug; 18(4):409-18. PubMed ID: 24604154
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
    Bisschop C; Ter Elst A; Bosman LJ; Platteel I; Jalving M; van den Berg A; Diepstra A; van Hemel B; Diercks GFH; Hospers GAP; Schuuring E
    Melanoma Res; 2018 Apr; 28(2):96-104. PubMed ID: 29232304
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Validation of Immunohistochemistry for the Detection of
    Gow CH; Hsieh MS; Lin YT; Liu YN; Shih JY
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234388
    [No Abstract]   [Full Text] [Related]  

  • 58. Accuracy of bone marrow histochemical TP53 expression compared to the detection of TP53 somatic mutations in patients with myelodysplastic syndromes harbouring a del5q cytogenetic abnormality.
    Oliva EN; Latagliata R; Sabattini E; Mammì C; Cuzzola M; D'Errigo MG; Cannatà MC; Bova I; Capodanno I; Palumbo GA; Pane F; Reda G; Fianchi L; Riva M; Poloni A
    Am J Blood Res; 2021; 11(4):417-426. PubMed ID: 34540351
    [TBL] [Abstract][Full Text] [Related]  

  • 59. VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting
    Choden S; Keelawat S; Jung CK; Bychkov A
    Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32150939
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases.
    Nielsen LB; Dabrosin N; Sloth K; Bønnelykke-Behrndtz ML; Steiniche T; Lade-Keller J
    Histopathology; 2018 Apr; 72(5):814-825. PubMed ID: 29119584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.